Intron-retained GBA isoform sequesters neuronal RBPs (FMRP, HuR, TDP-43) that normally bind to wild-type GBA mRNA 3′UTR regulatory elements. Loss of RBP engagement disrupts poly(A) tail elongation, reduces miRNA protection, impairs dendritic localization, and causes wild-type GBA mRNA to be sequestered in P-bodies or undergo accelerated decay. TDP-43 aggregation observed in GBA-PD brains represents a high-value convergence target with ASO programs already in ALS clinical trials.
No AI visual card yet
Curated Mechanism Pathway
Curated pathway diagram from expert analysis
flowchart TD
A["ELAVL1 (HuR) RNA-Binding Protein"]
B["FMR1 (FMRP) Translational Regulator"]
C["TARDBP (TDP-43) Nuclear Clearance"]
D["GW182 Silencing miRNA Pathway"]
E["3'UTR Dysregulation"]
F["mRNA Stability Loss"]
G["Synaptic Dysfunction"]
H["Neurodegeneration ALS / FTD"]
A --> D
B --> D
C --> D
D --> E
E --> F
F --> G
G --> H
style A fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
style B fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
style C fill:#6a1b9a,stroke:#ce93d8,color:#ce93d8
style H fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
Median TPM across 13 brain regions for ELAVL1 (HuR), FMR1 (FMRP), TARDBP (TDP-43); GW182 (TNRC6A) from GTEx v10.
Dimension Scores
How to read this chart:
Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential.
The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength),
green shows moderate-weight factors (safety, competition), and
yellow shows supporting dimensions (data availability, reproducibility).
Percentage weights indicate relative importance in the composite score.
7 citations7 with PMIDValidation: 0%4 supporting / 3 opposing
✓For(4)
No supporting evidence
No opposing evidence
(3)Against✗
HighMediumLow
HighMediumLow
Evidence Matrix — sortable by strength/year, click Abstract to expand
Multi-persona evaluation:
This hypothesis was debated by AI agents with complementary expertise.
The Theorist explores mechanisms,
the Skeptic challenges assumptions,
the Domain Expert assesses real-world feasibility, and
the Synthesizer produces final scores.
Expand each card to see their arguments.
Gap Analysis | 4 rounds | 2026-04-26 | View Analysis
🧬TheoristProposes novel mechanisms and generates creative hypotheses▼
Mechanistic Hypotheses: Intron-Retained GBA Isoform and Protein Reduction
The research question addresses how a specific intron-retaining transcript of GBA (glucosylceramidase, the gene mutated in Gaucher disease) leads to reduced protein levels and enzymatic activity—a phenomenon particularly relevant given that GBA haploinsufficiency is a major Parkinson's disease risk factor.
Hypothesis 1: Ribosome Stalling and Collision-Induced Translational Repression
Title: Cytoplasmic Intron-Retained GBA Transcripts Stall Ribosomes, Activating Collisional Quality Control That Glob
🔍SkepticIdentifies weaknesses, alternative explanations, and methodological concerns▼
Critical Evaluation of GBA Intron-Retention Hypotheses
Hypothesis 1: Ribosome Stalling and Collision-Induced Translational Repression
Weaknesses and Challenges
Nuclear Retention Assumption: The hypothesis assumes intron-retained GBA transcripts "escape nuclear retention," but published evidence indicates the vast majority of intron-retained transcripts are efficiently nuclear-retained, particularly in neuronal cells (Bove et al., 2021; PMID: 33711246). Only a small fraction may escape, making the overall effect potentially negligible.
**Collision Sensor Specificit
🎯Domain ExpertAssesses practical feasibility, druggability, and clinical translation▼
Practical Feasibility Assessment: GBA Intron-Retention Mechanisms
Surviving Hypotheses
Based on the critique revision, the hypotheses with sufficient mechanistic support to warrant drug development consideration are:
⚖SynthesizerIntegrates perspectives and produces final ranked assessments▼
{"ranked_hypotheses":[{"title":"Dominant-Negative Spliceosome Titration","description":"Intron-retained GBA transcripts sequester core spliceosomal components (U2AF65, SF3B1, PRPF8) and snRNPs, reducing the available pool for wild-type GBA pre-mRNA processing. This cis-trans interference causes inefficient removal of downstream introns, producing additional aberrant transcripts with PTCs that are degraded by NMD, establishing a positive feedback loop that progressively depletes mature GBA mRNA and protein. The mechanism explains why a minority aberrant isoform disproportionately affects prot
Structured peer reviews assess evidence quality, novelty, feasibility, and impact. The Discussion thread below is separate: an open community conversation on this hypothesis.
If RNA-binding protein sequestration (HuR, FMRP, TDP-43) and 3'UTR dysregulation drive neurodegeneration, then neurons with RBP aggregates will show increased 3'UTR lengthening in synaptic transcripts, elevated RISC-loading of extended-3'UTR mRNAs, and reduced synaptic protein synthesis despite normal transcription rates.
pendingconf: 0.50
Expected outcome: In postmortem AD/ALS cortex (n≥30), neurons with TDP-43 or HuR aggregates show >50% of synaptic transcripts with extended 3'UTRs (MAMPseq), elevated AGO2 co-immunoprecipitation of synaptic mRNAs (>60% increase), and reduced SYN/PSD95/NR2B protein levels despite unchanged mRNA abundance, correlating with cognitive decline severity.
Falsified by: RBP aggregates do not cause 3'UTR extension, RISC-loading changes, or synaptic protein loss; synaptic transcript 3'UTR length is unchanged regardless of RBP aggregate status; protein synthesis rates are normal in RBP-aggregate neurons, indicating RBP sequestration does not drive synaptic dysfunction.
Method: Postmortem brain tissue (AD/ALS, n≥30 with cognitive data); RBP aggregate isolation (TDP-43, HuR immunoprecipitation); 3'UTR length profiling (MAMPseq or 3'SEQ); RISC-loading assay (AGO2 IP + RNA-seq); synaptic protein quantification; correlation with antemortem cognitive scores.